EAST RUTHERFORD, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that third quarter 2018 financial results will be released on Thursday, November 8, 2018 before the market opens.

The Company will host a conference call to discuss the financial results.

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients (APIs), finished dosage forms, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing.  For more information, please visit www.cambrex.com.

Contact:  
Stephanie LaFiura                                                                              
Investor Relations Associate                                                             
Tel: 201-804-3037                                                      
Email: stephanie.lafiura@cambrex.com